In the late 1980s, a promising new treatment for breast cancer emerged: high-dose chemotherapy with autologous bone marrow transplantation or HDC/ABMT. By the 1990s, it had burst upon the oncology scene and disseminated rapidly before having been carefully evaluated. By the time published studies showed that the procedure was ineffective, more than 30,000 women had received the treatment, shortening their lives and adding to their suffering. This book tells of the rise and demise of HDC/ABMT for metastatic and early stage breast cancer, and fully explores the story`s implications, which go well beyond the immediate procedure, and beyond breast cancer, to how we in the United States evaluate other medical procedures, especially life-saving ones. It details how the factors that drove clinical use--patient demand, physician enthusiasm, media reporting, litigation, economic exploitation, and legislative and administrative mandates--converged to propel the procedure forward despite a lack of proven clinical effectiveness. It also analyzes the limited effect of technology assessments before randomized clinical trials evaluated decisively the procedure and the ramifications of this system on healthcare today. Sections of the book consider the initial conditions surrounding the emergence of the new breast cancer treatment, the drivers of clinical use, and the struggle for evidence-based medicine. A concluding section considers the significance of the story for our healthcare system.

尊敬的读者：
欢迎您访问我们的网站。本站的初衷是为大家提供一个共享学习资料、交换知识的平台。每位用户都可以将文件上传至网盘并分享。
然而，随着用户上传的资料增多，我们发现部分不宜或版权问题的书籍被分享到了本站。
为此，我们已经关闭了分享入口，并进行了多次书籍审查，但仍有部分内容未能彻底审查到位。
在此，我们恳请广大读者与我们共同监督，如发现任何不宜内容，请 点击此处 进行举报，我们会第一时间处理并下架相关内容。
希望我们能共建一个文明社区！感谢您的理解与支持！